AstraZeneca PLC (AZN)
| Market Cap | 252.87B +10.6% |
| Revenue (ttm) | 61.37B +8.6% |
| Net Income | 10.45B +25.9% |
| EPS | 6.68 +25.8% |
| Shares Out | 1.55B |
| PE Ratio | 24.21 |
| Forward PE | 15.05 |
| Dividend | $3.23 (2.00%) |
| Ex-Dividend Date | Aug 7, 2026 |
| Volume | 2,225,476 |
| Open | 164.47 |
| Previous Close | 164.21 |
| Day's Range | 161.46 - 164.48 |
| 52-Week Range | 149.50 - 212.71 |
| Beta | 0.21 |
| Analysts | Strong Buy |
| Price Target | 212.17 (+31.4%) |
| Earnings Date | Oct 30, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for AZN stock is "Strong Buy." The 12-month stock price target is $212.17, which is an increase of 31.40% from the latest price.
News
AstraZeneca PLC (AZN) Stock Down 1.2% -- Now Undervalued? GF Score: 78/100
AstraZeneca PLC (AZN) Stock Down 1.2% -- Now Undervalued? GF Score: 78/100
AstraZeneca takes a £1.5bn stake in US cancer drug developer as it steps up investment in America
The British drugs company has ploughed £1.5bn into US pharma firm Summit Therapeutics as part of a cancer treatment research joint venture.
AstraZeneca Stock Slips as $2 Billion Summit Stake Deepens Oncology
AstraZeneca Stock Slips as $2 Billion Summit Stake Deepens Oncology
AstraZeneca Pays $2 Billion To Get Into High-Profile Cancer Space
Summit Therapeutics stock catapulted Tuesday after AstraZeneca made a $2 billion investment in the smaller biotech.
Morning Movers: Summit Therapeutics jumps after AstraZeneca investment
Sstock futures have edged higher in early trading as technology stocks stabilize, but elevated oil prices and Treasury yields tied to ongoing Middle East tensions continue to temper risk appetite.
AstraZeneca (AZN) Shares Rise 2% Premarket on Cancer Therapy Investment
AstraZeneca (AZN) Shares Rise 2% Premarket on Cancer Therapy Investment
Summit Therapeutics jumps 20% after AstraZeneca's $2 billion bet: what it signals
Summit Therapeutics shares surged more than 20% in pre-market trading on Tuesday after AstraZeneca agreed to invest $2 billion in the company and collaborate on a series of clinical studies involving ...
Why Is Summit Therapeutics Stock (SMMT) Soaring in Premarket Today, Sept. 29?
Summit Therapeutics ($SMMT) stock is up 22% in Tuesday’s premarket trading. The gain came after AstraZeneca ($AZN) announced a $2 billion equity investment in Summit Therapeutics and a deal to…
Summit soars after $2 billion investment from AstraZeneca for cancer therapies
Summit Therapeutics' shares rose 23% in premarket trading on Tuesday after the drugmaker said AstraZeneca would invest $2 billion in the company to test cancer treatments together.
FTSE 100 rises as AstraZeneca lifts healthcare sector
London's FTSE 100 rose on Tuesday, lifted by pharmaceutical stocks after AstraZeneca agreed to take a $2 billion stake in Summit Therapeutics to advance cancer research.
AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows
Shares of Akeso surged after British drug maker AstraZeneca moved to advance the Chinese biotech firm’s flagship cancer drug, while a new deal from US giant Merck further underscored the sector’s glob...
AstraZeneca invests £1.5bn into US firm Summit for cancer drug tie-up
The firms will collaborate on Summit’s experimental new medicine as well as researching how it could be combined with Astra’s treatments.
Anthropic warns of ‘existential risks to humanity' from AI; AstraZeneca makes $2bn cancer drug tie-up – business live
Rolling coverage of the latest economic and financial news
HUTCHMED Seeks FDA Approval For ORPATHYS-TAGRISSO In Resistant Lung Cancer
(RTTNews) - HUTCHMED (HCM) announced that AstraZeneca (AZN) has submitted a New Drug Application to the U.S. FDA for ORPATHYS in combination with TAGRISSO for certain patients with advanced non-small ...
AstraZeneca Invests $2 Billion In Summit, Expands Cancer Drug Collaboration; Stock Up
(RTTNews) - AstraZeneca (AZN) has agreed to make a $2 billion strategic equity investment in Summit Therapeutics (SMMT) while launching a clinical collaboration aimed at advancing new cancer treatment...
AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination
HUTCHMED (China) said on Tuesday Anglo-Swedish drugmaker AstraZeneca had filed an application with the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination in pat...
Hutchmed says AstraZeneca submits NDA for ORPATHYS+TAGRISSO in NSCLC
Hutchmed (HCM) “announces that AstraZeneca (AZN) has submitted a New Drug Application to the US Food and Drug Administration for ORPATHYS (savolitinib) plus TAGRISSO(R) (osimertinib) for the treatment...
Closing Bell Movers: Summit Therapeutics jumps on AstraZeneca investment
Major indices started the week on a downswing as oil prices sprang higher after President Donald Trump rejected conditions for a ceasefire presented by Iran and Treasury yields extended their…
AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs
Summit shares surged in after-hours trading following the news of AstraZeneca's investment, as the two companies plan to ramp up their collaboration on developing cancer treatments.
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up
Summit Therapeutics said on Monday that British drugmaker AstraZeneca would invest $2 billion in the company and collaborate on a series of studies testing their cancer treatments together.
Summit Therapeutics up 15% after AstraZeneca makes $2B equity investment
In after-hours trading, shares of Summit Therapeutics (SMMT) are up 15% to $17.85.
Summit Therapeutics, AstraZeneca enter clinical collaboration agreement
Summit (SMMT) entered into a clinical collaboration agreement with AstraZeneca (AZN) to evaluate sonesitatug vedotin in combination with ivonescimab with the intent to start studies in certain gastroi...
AstraZeneca makes $2B equity investment in Summit Therapeutics
Summit Therapeutics (SMMT) announced key developments important to the company’s progress towards achieving its goal of making a significant difference in the lives of patients with cancer. Specifical...
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced key developments important to the company's progress towards achieving its goal of making a significant difference in th...
Eccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004)
BOSTON & SHANGHAI--(BUSINESS WIRE)--Eccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004).